Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure.
复制标题
DOI：
10.5935/abc.20140205
复制
发表时间：
2015-04
影响因子：
2.6
通讯作者：
Carvalho H
中科院分区：
文献类型：
--
作者：
Ferreira JP;Santos M;Oliveira JC;Marques I;Bettencourt P;Carvalho H
基质金属蛋白酶（MMP）是一个重要的酶家族的细胞外基质的吸收，控制血管重塑和修复。在心力衰竭中已经证明MMP 2活性增加，并且在急性失代偿性心力衰竭（ADHF）中，已经证明循环MMP的减少与成功的治疗一起沿着。我们的目的是测试螺内酯对MMP 2水平的影响。一项前瞻性、干预性研究的次要分析，包括100例ADHF患者。50例患者被非随机分配到螺内酯（100 mg/天）加标准ADHF治疗（螺内酯组）或仅标准ADHF治疗（对照组）。螺内酯组患者较年轻，肌酐和尿素水平较低（均P < 0.05）。螺内酯组和对照组之间的基线MMP 2、NT-pro BNP和体重没有差异。在螺内酯组中观察到MMP 2从基线至第3天更明显降低的趋势（-21 [-50至19] vs 1.5 [-26至38] ng/mL，p = 0.06）。NT-pro BNP和体重在螺内酯组中也有更大的下降。从基线到第3天MMP 2水平降低的患者比例在螺内酯组中也可能更高（50% vs 66.7%），但无统计学意义。MMP 2、NT-pro BNP与体重变化的相关性无统计学意义。ADHF中MMP 2水平升高。接受安体舒通治疗的患者可能会使MMP 2水平大幅降低。
Matrix metalloproteinases (MMPs) are a family of enzymes important for the resorption of extracellular matrices, control of vascular remodeling and repair. Increased activity of MMP2 has been demonstrated in heart failure, and in acutely decompensated heart failure (ADHF) a decrease in circulating MMPs has been demonstrated along with successful treatment. Our aim was to test the influence of spironolactone in MMP2 levels. Secondary analysis of a prospective, interventional study including 100 patients with ADHF. Fifty patients were non-randomly assigned to spironolactone (100 mg/day) plus standard ADHF therapy (spironolactone group) or standard ADHF therapy alone (control group). Spironolactone group patients were younger and had lower creatinine and urea levels (all p < 0.05). Baseline MMP2, NT-pro BNP and weight did not differ between spironolactone and control groups. A trend towards a more pronounced decrease in MMP2 from baseline to day 3 was observed in the spironolactone group (-21 [-50 to 19] vs 1.5 [-26 to 38] ng/mL, p = 0.06). NT-pro BNP and weight also had a greater decrease in the spironolactone group. The proportion of patients with a decrease in MMP2 levels from baseline to day 3 was also likely to be greater in the spironolactone group (50% vs 66.7%), but without statistical significance. Correlations between MMP2, NT-pro BNP and weight variation were not statistically significant. MMP2 levels are increased in ADHF. Patients treated with spironolactone may have a greater reduction in MMP2 levels.
登录
查看更多内容
影响因子：
9.7
作者：
Biolo, Andreia;Fisch, Mark;Colucci, Wilson S.
通讯作者：
Colucci, Wilson S.
影响因子：
4.3
作者：
Tyagi, SC;Campbell, SE;Voelker, DJ
通讯作者：
Voelker, DJ
DOI：
10.1046/j.1365-2362.2003.01187.x
发表时间：
2003-08-01
影响因子：
5.5
作者：
Altieri, P;Brunelli, C;Ghigliotti, G
通讯作者：
Ghigliotti, G
影响因子：
37.8
作者：
Bettencourt, P;Azevedo, A;Ferreira, A
通讯作者：
Ferreira, A
影响因子：
39.2
作者：
Levey AS;Stevens LA;Schmid CH;Zhang YL;Castro AF 3rd;Feldman HI;Kusek JW;Eggers P;Van Lente F;Greene T;Coresh J;CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
通讯作者：
CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)